Lonza to Acquire Five Merck CDMO Sites, Doubles US Manufacturing Footprint
Lonza is acquiring five CDMO facilities from Merck KGaA for low to mid-triple-digit millions of Swiss francs, expanding its US presence. The deal adds nine facilities, 1,100 employees, and capabilities in bioconjugates, viral vectors, and advanced drug delivery. Lonza expects CHF 250M in sales by 2028, with integration expected to drive future growth. The transaction is set to close by mid-2027.
How this was made
The 30-second read
Why it matters
The deal expands Lonza’s US network from four to nine facilities and adds modality-specific capabilities (bioconjugates, high-potency payload-linkers, viral vectors with aseptic fill-finish, and LNP/liposomes/PEGylated proteins with aseptic fill-finish). Financially, the acquired operations are expected to generate about CHF 250 million in full-year 2028 sales, with CORE EBITDA margin below Lonza’s existing group margin initially, and peak sales at group-margin level by the mid-2030s.
Market read
Traders can reassess CDMO capacity and modality exposure, deal-financing risk, and longer-term margin trajectory ahead of integration milestones.
What to watch
Regulatory and customer qualification timelines for new sites, competitive responses from other CDMOs, and whether demand growth for bioconjugates and viral vectors sustains through the mid-2030s peak margin ramp.
Background
Lonza and Merck KGaA have agreed on a definitive transaction where Lonza will buy five US CDMO facilities from Merck KGaA to expand specialized manufacturing capabilities.
Ticker impact
Merck KGaA is the seller of five US CDMO facilities to Lonza, divesting assets to concentrate its Life Science portfolio.
Likely limited immediate impact, with sentiment depending on how investors view proceeds use and the strategic focus versus lost CDMO earnings.
The article describes Merck KGaA’s strategic rationale and divestment framing, but does not provide Merck KGaA-specific financial impact beyond the buyer’s sales expectations and deal value.
Market effects
Signals continued consolidation and capacity build-out in biopharmaceutical CDMO, particularly for ADCs, viral vectors, and advanced drug-delivery modalities.
Increases US manufacturing footprint and employment for Lonza, potentially tightening capacity availability for US-based biopharma customers.
Reinforces global shift toward specialized modalities and end-to-end manufacturing capabilities, influencing competitive positioning across CDMO networks.
Counterpoint
Initial CORE EBITDA margin below Lonza’s group margin and “insignificant” near-term contribution could limit upside until integration and ramp progress.
Key entities
- companyLonza
Buyer of five Merck KGaA CDMO facilities to expand US manufacturing footprint and specialized biopharma capabilities.
- companyMerck KGaA
Seller of five US CDMO facilities as part of a Life Science portfolio concentration strategy.
